Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

12.09.06	Exubera Hailed as Innovation In Prestigious European and American Awards (PR Newswire)
05.09.06	New Lipitor Data Published in The Lancet (PR Newswire)
07.08.06	Icagen Announces the Appointment of Adeoye Y. Olukotun, M.D., MPH, FACC to the Company's Board of Directors (Businesswire)
03.08.06	Palatin Technologies and King Pharmaceuticals Report Results of a Clinical Study Evaluating Bremelanotide in Post-Menopausal Female Sexual Dysfunction Patients (PR Newswire)
26.06.06	OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R)(pegaptanib sodium injection) Maintenance Trial in Neovascular Age-Related Macular Degeneration (AMD) (Businesswire)
23.06.06	AUDIO from Medialink: Dad... Are Our Hands Clean Yet? (Businesswire)
31.05.06	Icagen Initiates Pediatric Clinical Development of ICA-17043 for Sickle Cell Disease (Businesswire)
08.05.06	Pfizer and Monogram to Make HIV Co-Receptor Tropism Assay Available Globally (PR Newswire)
25.04.06	Abraxis BioScience to Acquire European and U.S. Compliant Manufacturing Complex from Pfizer (Businesswire)
03.04.06	Pfizer to Deploy Siperian Hub to Create Consolidated Customer Master in Preparation for Major European & Canadian CRM Initiative (PR Newswire)
28.03.06	Icagen to Webcast Upcoming Sickle Cell Disease Day Investor and Analyst Meeting (Businesswire)
14.03.06	Neue Studie beweist: Lipitor erzielt verbesserte Nierenfunktion bei Patienten mit koronarer Herzerkrankung (PR Newswire)
13.03.06	Seven Summits Research Releases Comments on PFE, CVX, VOD, ABT, and WM (PR Newswire)
02.03.06	Seven Summits Research Releases Comments on PFE, BRCM, MO, ECA, and LU (PR Newswire)
02.03.06	NicOx Compound Demonstrates Excellent Preclinical Results in Pfizer Glaucoma Collaboration (PR Newswire)
01.03.06	Icagen Reports Fourth Quarter and Full Year 2005 Financial Results (Businesswire)
21.02.06	Pfizer unterstützt neuen elektronischen Risiko-Rechner für Grünen Star anlässlich des World Ophthalmology Congress vorgestellt (Businesswire)
10.11.05	Pain Therapeutics and King Pharmaceuticals Enter Into Strategic Alliance to Develop and Commercialize Remoxy(TM) (PR Newswire)
09.11.05	King Pharmaceuticals Reports Third-Quarter 2005 Financial Results (PR Newswire)
01.11.05	King Pharmaceuticals Announces Resolution With Medicaid and Other Governmental Pricing Programs (PR Newswire)
15.10.05	El Mes De La Herencia Hispana Nos Recuerda Que Un Numero Creciente De Hispanos No Tiene Un Cuidado De Salud De Calidad (Businesswire)
27.09.05	FDA Approves Lipitor(R) (atorvastatin calcium) to Reduce Stroke Risk (Businesswire)
27.09.05	FDA Approves Cholesterol-Lowering Drug to Reduce Stroke Risk (Businesswire)
13.09.05	Inyx Updates Financial Guidance for 2005 and 2006 (PR Newswire)
12.09.05	Stephen Beckman Joins Inyx as Vice President Sales & Marketing and Commercial Development (PR Newswire)
04.09.05	Patients Taking a Regimen Based On Pfizer's Norvasc Experienced Significant Reductions In Cardiovascular Death, Landmark Study Shows (PR Newswire)
09.08.05	King Pharmaceuticals Reports Second-Quarter 2005 Financial Results (PR Newswire)
08.08.05	Early Use of Pfizer's Inspra(R) (Eplerenone) Significantly Reduced Death Rates Among Heart Attack Patients With Reduced Heart Muscle Function and Signs of Heart Failure (PR Newswire)
01.08.05	King Pharmaceuticals Announces Date for Release of Second-Quarter 2005 Financial Results and Conference Call (PR Newswire)
23.06.05	Palatin Technologies Settles Claim in License Agreement Dispute with Competitive Technologies (PR Newswire)
14.06.05	Data Presented at American Diabetes Association Scientific Sessions Support Exubera(R) Efficacy and Safety Profile In Type 1 and Type 2 Diabetes (PR Newswire)
07.04.05	Palatin Technologies and King Pharmaceuticals Announce Formation of Sc (PR Newswire)
08.02.05	Palatin Technologies, Inc. and King Pharmaceuticals, Inc. Report Posit (PR Newswire)
12.01.05	UK Patients Concerned that Lack of Health Information is Worsening the (Businesswire)
12.01.05	European Patients Want More Health Information - 1 - To Better Manage (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V

mehr

10.01.25		Börse Zürich: SPI fällt zum Ende des Freitagshandels zurück
10.01.25		Angespannte Stimmung in Frankfurt: LUS-DAX notiert zum Handelsende im Minus
10.01.25		Schwacher Handel: DAX liegt letztendlich im Minus
10.01.25		Freitagshandel in Europa: Euro STOXX 50 gibt zum Handelsende nach
10.01.25		Schwacher Wochentag in London: FTSE 100 beendet den Handel in der Verlustzone
10.01.25		Bayer-Aktie profitiert: Niedrig dosiertes MRT-Kontrastmittel von Bayer besteht Phase-3-Studie - Zulassung für Kerendia in USA und China beantragt
10.01.25		Dezember 2024: Analysten sehen Potenzial bei Novartis-Aktie

10.01.25

Börse Zürich: SPI fällt zum Ende des Freitagshandels zurück

10.01.25

Angespannte Stimmung in Frankfurt: LUS-DAX notiert zum Handelsende im Minus

10.01.25

Schwacher Handel: DAX liegt letztendlich im Minus

10.01.25

Freitagshandel in Europa: Euro STOXX 50 gibt zum Handelsende nach

10.01.25

Schwacher Wochentag in London: FTSE 100 beendet den Handel in der Verlustzone

10.01.25

Bayer-Aktie profitiert: Niedrig dosiertes MRT-Kontrastmittel von Bayer besteht Phase-3-Studie - Zulassung für Kerendia in USA und China beantragt